Unknown

Dataset Information

0

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.


ABSTRACT: PURPOSE:We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib. Materials and Methods:We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFR-mutant NSCLC at Samsung Medical Center between 2014 and 2016. RESULTS:In total, 467 patients received first-line afatinib (n=165), gefitinib (n=230), or erlotinib (n=72). Afatinib was used more often in patients with tumors harboring deletion in exon 19 (Del19), whereas the gefitinib group had more elderly, females, and never smokers. The median progression-free survival (PFS) time for afatinib, gefitinib, and erlotinib was 19.1 months, 13.7 months, and 14.0 months, respectively (p=0.001). The superior PFS of afatinib was more remarkable in subgroups of Del19 or uncommon EGFR mutations. Overall toxicity profiles of the three drugs were comparable, though more grade 3 or 4 toxicities were detected in afatinib (7.3%) compared with gefitinib (2.6%) or erlotinib (1.8%). The common grade 3 or 4 toxicities of afatinib included diarrhea (3.0%), paronychia (2.4%), and skin rash (1.8%). Dose modification was more frequently required in patients treated with afatinib (112/165, 68%), compared with gefitinib (5/230, 2%) and erlotinib (4/72, 6%). Interestingly, however, dose reduction in the afatinib group did not impair its efficacy in terms of PFS (dose reduction vs. no reduction group, 23.5 months vs. 12.4 months). CONCLUSION:First-line afatinib showed satisfactory efficacy data and manageable toxicity profiles.

SUBMITTER: Kim Y 

PROVIDER: S-EPMC6473268 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.

Kim Youjin Y   Lee Se-Hoon SH   Ahn Jin Seok JS   Ahn Myung-Ju MJ   Park Keunchil K   Sun Jong-Mu JM  

Cancer research and treatment 20180613 2


<h4>Purpose</h4>We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib.<h4>Materials and methods</h4>We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFR-mutant NSCLC at Samsung Medical Center between 2014 and 2016.<h4>Results</h4>In total, 467 patients received first-  ...[more]

Similar Datasets

| S-EPMC3922700 | biostudies-literature
| S-EPMC6754576 | biostudies-literature
| S-EPMC4769992 | biostudies-literature
| S-EPMC3186869 | biostudies-literature
| S-EPMC3601073 | biostudies-literature
| S-EPMC2596582 | biostudies-literature
| S-EPMC7607055 | biostudies-literature
| S-EPMC4200993 | biostudies-literature
| S-EPMC4715986 | biostudies-literature
| S-EPMC4770714 | biostudies-literature